The Executive Guide to Funding & M&A in 2026
A working brief for leaders evaluating funding & m&a investments: evidence, market reality, and the questions that matter.
Every technology budget tells a story, and in funding & m&a the 2026 story is one of consolidation, evidence, and reimbursement finally catching up with capability. This guide distills what we hear from operators and what the data shows into a working brief for executives.
Start with the problem, not the product
The costliest failures in this category share a root cause: technology purchased before the workflow, staffing, and payment model to absorb it existed. The discipline that separates successful programs is unglamorous - governance first, a narrowly scoped pilot second, measurement third, and scale only when the first three hold.
The market reality
Consider the current numbers: uS digital health startups raised $7.4 billion across 244 deals in H1 2026, with 45% of capital in $100M+ megadeals (our analysis).
Meanwhile, 115 acquisitions made the first half the busiest M&A run since 2021.
Meanwhile, talkiatry's $210 million Series D anchored mental health's seventh straight year atop the clinical funding charts (our coverage).
Meanwhile, garner Health raised back-to-back rounds reaching a $2.74 billion valuation (our coverage).
Questions to ask every vendor
Where is the peer-reviewed or real-world evidence, and on a population like ours? What happens to our data - who trains on it, who profits from it? What does integration actually require from our EHR team? And what is the exit: if we terminate, what do we keep? Vendors comfortable with these questions tend to be the ones still standing in three years.
The bottom line
Funding & M&A rewards patient, evidence-driven adopters. Track the category daily on our Funding & M&A page and the topic feeds beneath it.